Verition Fund Management LLC acquired a new stake in Harrow, Inc. (NASDAQ:HROW - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 21,147 shares of the company's stock, valued at approximately $951,000. Verition Fund Management LLC owned approximately 0.06% of Harrow as of its most recent filing with the SEC.
A number of other institutional investors also recently made changes to their positions in the business. Quest Partners LLC purchased a new stake in Harrow during the third quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Harrow by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,283 shares of the company's stock valued at $57,000 after acquiring an additional 227 shares during the period. nVerses Capital LLC bought a new position in Harrow during the 2nd quarter worth approximately $33,000. Allspring Global Investments Holdings LLC grew its position in Harrow by 2,730.7% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company's stock worth $44,000 after acquiring an additional 2,048 shares during the last quarter. Finally, Hills Bank & Trust Co purchased a new position in Harrow in the 3rd quarter worth approximately $107,000. Hedge funds and other institutional investors own 72.76% of the company's stock.
Harrow Trading Up 1.6 %
HROW stock traded up $0.63 on Monday, reaching $39.95. The company's stock had a trading volume of 314,147 shares, compared to its average volume of 508,393. The firm has a market cap of $1.42 billion, a PE ratio of -42.50 and a beta of 0.69. The business has a fifty day simple moving average of $46.99 and a two-hundred day simple moving average of $35.65. Harrow, Inc. has a 12-month low of $9.13 and a 12-month high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55.
Analysts Set New Price Targets
Several brokerages have recently issued reports on HROW. Lake Street Capital raised their target price on shares of Harrow from $45.00 to $55.00 and gave the stock a "buy" rating in a report on Friday, October 4th. Craig Hallum raised their price target on shares of Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a report on Friday, October 4th. Finally, B. Riley lowered their price objective on shares of Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research note on Wednesday, December 4th.
Read Our Latest Report on Harrow
Harrow Profile
(
Free Report)
Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Further Reading
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.